Recombinant Human IL‑17/IL‑17A induces CXCL1/GRO alpha secretion in the HT‑29 human colon adenocarcinoma cell line in a dose-dependent manner (orange line), as measured by the Human CXCL1/GRO alpha DuoSet ...read more
K562 human chronic myelogenous leukemia cell line was stained with Mouse Anti-Human IL-17 R Monoclonal Antibody (Catalog # MAB177, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram) ...read more
Genetic Strategies: IL-17 RA/IL-17 R knockout K562 human myelogenous leukemia cell line was stained with Mouse Anti-Human IL-17 RA/IL-17 R Monoclonal Antibody (Catalog # MAB177, filled histogram) or isotype ...read more
Mouse myeloma cell line NS0-derived recombinant human IL‑17 RA/IL‑17 R Leu33-Trp320 Accession # Q96F46
Detects human IL‑17 RA/IL‑17 R in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant mouse (rm) IL‑17 R, rmIL‑17B R, or recombinant human IL‑17B R is observed. In Western blots, no cross-reactivity with rmIL-17 R is observed
Details of Functionality
ActivityAssaywCitation not found None None None None
<0.10 EU per 1 μg of the antibody by the LAL method.
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.5 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for IL-17RA/IL-17R Antibody (133617) [Unconjugated]
CDw217interleukin 17 receptor
IL-17 receptor A
IL17Rinterleukin-17 receptor A
interleukin 17 receptor A
Interleukin 17 (also known as CTLA-8) is a T cell-expressed pleotropic cytokine. IL-17 binds to IL-17 receptor (IL-17 R) which shares no homology with any known family of receptors. While the expression of IL-17 is restricted to activated T cells, the IL-17 R mRNA exhibits a broad tissue distribution, and has been detected in virtually all cells and tissues tested. Human IL-17 R is a 120 kDa, 866 amino acid (aa) type I membrane glycoprotein with a 293 aa extracellular domain, a 21 aa carboxy-proximal transmembrane domain, and a 525 aa cytoplasmic tail. Within the ECD, human IL-17 R shares 72% aa sequence identity with mouse and rat IL‑17 R. The signaling events of IL-17 includes activation of NF-kappa B and JNK, and require TNF receptor-associated factors 6 (TRAF6) in the signaling pathway.
Yao, Z. et al. (1997) Cytokine 9:794.
Schwander, R. et al. (2000) J. Exp. Med. 191:1233.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our IL-17RA/IL-17R Antibody (133617) [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.